Skip to main content

Aktis Oncology, Inc.

corporate_fare Company Profile

Aktis Oncology, Inc.

AKTS·NASDAQ·Life Sciences·CIK 0002035832

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company is developing next-generation technologies intended to broaden the cancer patient populations that can benefit from targeted radiopharmaceuticals by expanding the scope of tumor targets for which a powerful payload of an alpha-emitting radioisotope can be safely delivered. To ensure patient demand is reliably met, Aktis Oncology is also establishing efficient end-to-end supply through a combination of critical internal capabilities paired with established external vendors. Through these efforts, the company seeks to maximize clinical utility across multiple indications in multiple tumor types and to expand commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting into the more expansive clinical oncology setting. Aktis Oncology has built a proprietary miniprotein radioconjugate platform designed to safely confer breakthrough efficacy to a broad range of patient populations. Its miniprotein radioconjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged tumor retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. The company states that its miniproteins have demonstrated the ability to potently bind to tumor targets outside the scope of current delivery technologies such as peptide-based radioconjugates. The source notes that the field of targeted radiopharmaceuticals is currently led by two marketed products targeting prostate specific membrane antigen or somatostatin-2 receptor, each currently approved in only one tumor type, and that many emerging companies remain primarily focused on these same two targets.

Aktis Oncology, Inc. (NASDAQ:AKTS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for AKTS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aktis Oncology Adopts Restrictive Governance Post-IPO
  • Aktis Oncology Completes Initial Public Offering, Raising $291M to Fund Radiopharmaceutical Pipeline
  • Aktis Oncology Files for IPO to Raise Up to $316.4M to Advance Radiopharmaceutical Pipeline
  • Aktis Oncology Files S-1/A for Initial Public Offering to Raise Up to $209.6M for Radiopharmaceutical Pipeline
$16.46 +1.92% today
52-week range · as of 2026-11-12 $13.96 – $34.19
Market cap
$898.25M
Volume
375K (1.0× avg)
3-mo avg 378.5K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AKTS - Filings & News (Page 2)

AKTS
Jan 12, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.76
Real-time Price: $16.46 info
Change: -$5.30 (-24%) info
Market Cap: $898.255M info
AKTS
Jan 09, 2026, 5:01 PM EST
Filing Type: 424B4
Importance Score:
9
Price at Filing: $22.40
Real-time Price: $16.46 info
Change: -$5.94 (-27%) info
Market Cap: $898.255M info
AKTS
Jan 07, 2026, 7:19 AM EST
Filing Type: S-1/A
Importance Score:
9
Price at Filing: $0.0372
Real-time Price: $16.46 info
Change: +$16.42 (+44,147%) info
Market Cap: $898.255M info
AKTS
Jan 05, 2026, 6:32 AM EST
Filing Type: S-1/A
Importance Score:
8
Price at Filing: $0.0372
Real-time Price: $16.46 info
Change: +$16.42 (+44,147%) info
Market Cap: $898.255M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets